Immix Biopharma announced on September 18, 2025, that it has surpassed the 50% enrollment milestone in its NEXICART-2 clinical trial. This trial is evaluating the sterically-optimized CAR-T NXC-201 for relapsed/refractory AL Amyloidosis. The company continues to enroll patients expediently, aiming for a Biologics License Application (BLA) submission.
The CEO, Ilya Rachman, attributed the rapid enrollment to the excitement generated by the clinical results presented at ASCO 2025. This growing interest among clinicians and patients highlights the significant unmet need in relapsed/refractory AL Amyloidosis, where no FDA-approved drugs are currently available.
Surpassing this enrollment milestone accelerates the path to NEXICART-2 BLA submission for FDA approval. It also supports future commercial awareness for NXC-201, reinforcing the company's progress in bringing this therapy to market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.